The mysteries of lipoprotein(a) and cardiovascular disease revisited.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Positive correlation between variants of lipid metabolism‑related genes and coronary heart disease.Molecular medicine reports · 2013
   Pooled it
2. Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage.International journal of molecular sciences · 2025
   Review
3. Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review.Vascular health and risk management · 2025
   Review
4. Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a).Drugs in context · 2024
   Review
5. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.Current cardiology reports · 2023
   Review
6. The Anti-Thrombotic Effects of PCSK9 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2023
   Review
7. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.Cardiovascular ultrasound · 2023
   Article
8. Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study.Thrombosis journal · 2022
   Article
9. Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.Journal of clinical medicine · 2022
   Review
10. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.Biomolecules · 2021
    Review
11. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.Current atherosclerosis reports · 2019
    Review
12. Relation of Plasma Lipoprotein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans With a Family History of Early-Onset Coronary Artery Disease.The American journal of cardiology · 2016
    Article
13. Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention.Texas Heart Institute journal
    Article

Corrections and comments

• Comment on
  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as